A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma

被引：0
|
作者：
O'Day, Steven
Gonzalez, Rene
Kim, Kevin
Chmielowski, Bartosz
Kefford, Richard
Long, Georgina
Loquai, Carmen
Cowey, Charles Lance
Hauschild, Axel
Hainsworth, John D.
Hersey, Peter
Boyle, Frances
Evans, T. R. Jeffry
Hamid, Omid
Meneses, Nicole
Andresen, Corina
Ren, Min
O'Brien, James P.
Flaherty, Keith
机构：
[1] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[2] UCHSC, Aurora, CO USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Westmead Hosp, Westmead, NSW 2145, Australia
[6] Univ Sydney, Sydney, NSW 2006, Australia
[7] Johannes Gutenberg Univ Mainz, Univ Med, D-55122 Mainz, Germany
[8] Texas Oncol, Dallas, TX USA
[9] Univ Klinikum Schleswig Holstein, Kiel, Germany
[10] Sarah Cannon Res Inst, Nashville, TN USA
[11] Tennessee Oncol, Nashville, TN USA
[12] Calvary Mater Newcastle, Waratah, Australia
[13] Melanoma Inst Australia, Sydney, NSW, Australia
[14] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[15] Angeles Clin & Res Inst, Los Angeles, CA USA
[16] Eisai Inc, Woodcliff Lake, NJ USA
[17] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9026
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma
    Sachdev, Pallavi
    Hamid, Omid
    Kim, Kevin
    Hauschild, Axel
    O'Day, Steven
    Andresen, Corina
    Funahashi, Yasuhiro
    Kadowaki, Tadashi
    O'Brien, James P.
    Flaherty, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients
    Guadagni, Stefano
    Zoras, Odysseas
    Fiorentini, Giammaria
    Masedu, Francesco
    Lasithiotakis, Konstantinos
    Sarti, Donatella
    Farina, Antonietta Rosella
    Mackay, Andrew Reay
    Clementi, Marco
    JOURNAL OF SURGICAL RESEARCH, 2021, 268 : 737 - 747
  • [3] Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma
    Algazi, Alain Patrick
    Muthukumar, Adele H.
    O'Brien, Kelly
    Lencioni, Alex
    Tsai, Katy K.
    Kadafour, Maha
    Chapman, Paul B.
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Targeting the MAPK pathway in advanced BRAF wild-type melanoma
    Massa, R. C.
    Kirkwood, J. M.
    ANNALS OF ONCOLOGY, 2019, 30 (04) : 503 - 505
  • [5] MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma
    Orouji, Elias
    Orouji, Azadeh
    Gaiser, Timo
    Larribere, Lionel
    Gebhardt, Christoffer
    Utikal, Jochen
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (09) : 2257 - 2262
  • [6] Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
    Robert, Caroline
    Long, Georgina V.
    Brady, Benjamin
    Dutriaux, Caroline
    Di Giacomo, Anna Maria
    Mortier, Laurent
    Rutkowski, Piotr
    Hassel, Jessica C.
    McNeil, Catriona M.
    Kalinka, Ewa Anna
    Lebbe, Celeste
    Charles, Julie
    Hernberg, Micaela M.
    Savage, Kerry J.
    Chiarion-Sileni, Vanna
    Mihalcioiu, Catalin
    Mauch, Cornelia
    Arance, Ana
    Cognetti, Francesco
    Ny, Lars
    Schmidt, Henrik
    Schadendorf, Dirk
    Gogas, Helen
    Zoco, Jesus
    Re, Sandra
    Ascierto, Paolo A.
    Atkinson, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (33) : 3937 - 3946
  • [7] A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas W.
    McCaffrey, Judith
    Newbold, Kate
    Allison, Roger
    Martins, Renato G.
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn
    Funahashi, Yasuhiro
    Ren, Min
    O'Brien, James P.
    Sherman, Steven I.
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 44 - 53
  • [8] A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas Wilmot
    McCaffrey, Judith C.
    Newbold, Kate
    Allison, Roger
    Martins, Renato
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn A.
    Funahashi, Yasuhiro
    Sellecchia, Rita
    Andresen, Corina
    O'Brien, James P.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Ueno, Hideki
    Nakachi, Kohei
    Morizane, Chigusa
    Kondo, Shunsuke
    Shimizu, Satoshi
    Kojima, Yasushi
    Suzuki, Takuya
    Tamai, Toshiyuki
    O'Brien, James P.
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [10] cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines
    Journe, F.
    Wiedig, M.
    Morandini, R.
    Sales, F.
    Ghanem, G.
    Awada, A.
    EJC SUPPLEMENTS, 2010, 8 (07): : 83 - 84
12345